Merck Jessie EnglishMerck KGaA has appointed Dr Jessie English as its new vice president of discovery, transnational innovation platform immuno-oncology.
She will take up her new role on 16 February, when she will lead the discovery team’s efforts in the exploration of disease targets and translating these into patient care.
Dr English joins Merck from the Belfer Institute for Applied Cancer Sciences at Havard Medical School’s Dana-Farber Cancer Institute where she had been head of research since March 2012.
During her two decades of work in oncology and immune-oncology research, she has also served as vice president of kinase biology at ArQule, oncology site lead for external discoveries at Merck Research Laboratories.
Prior to that she held leadership positions at both Pfizer Research and Schering-Plough Research Institute.
Source: PMLive
NutritionInsight speaks with Lindsey Toth, associate director of product management at DFS & Ingredients, Lonza Capsules & Health Ingredients.
The company was created in 2020 by Novo Seeds, which worked closely with the founders to develop a commercially attractive business plan to maximise the potential of Hemab’s promising technology platform.
BD (Becton, Dickinson and Company) announced today it has acquired Tepha, Inc., a leading developer and manufacturer of a proprietary resorbable polymer technology.
